Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, published in Science, from researchers at the Perelman School of Medicine at the ...

The new vaccine is "personalized," meaning it is designed to train the patient's immune system to recognize and eliminate any remaining cells of that person's cancer.

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

The incidence rate of cases increased 6.7% per year on average between 2011 and 2021, the JAMA-published research revealed.

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell ca ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...